Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional Office in San Francisco, a major HIV drug maker ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Gilead Sciences has been the center of investor activism ... expanded its portfolio in critical therapeutic areas like HIV, liver disease, and oncology, with new therapies such as lenacapavir ...

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

Gilead Sciences (NASDAQ:GILD – Get Free Report ... and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa ...

Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in ...